Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Styblo refined "a treatment system of checks and balances that provided high cure rates at a cost affordable for most developing countries." This increased the proportion of people cured of TB from 40% to nearly 80%, costing up to $10 per life saved and $3 per new infection avoided. [3]
The goal of tuberculosis elimination is hampered by the lack of rapid testing, short and effective treatment courses, and completely effective vaccine. [2] The WHO as well as the Stop TB Partnership aim for the full elimination of TB by 2050—requiring a 1000-fold reduction in tuberculosis incidence. [3]
Effective TB treatment is difficult, due to the unusual structure and chemical composition of the mycobacterial cell wall, which hinders the entry of drugs and makes many antibiotics ineffective. [137] Active TB is best treated with combinations of several antibiotics to reduce the risk of the bacteria developing antibiotic resistance. [14]
“The patient and her family gave us permission to share this update,” the local health department reported Monday.
Treatment of MDR-TB requires treatment with second-line drugs, usually four or more anti-TB drugs for a minimum of 6 months, and possibly extending for 18–24 months if rifampin resistance has been identified in the specific strain of TB with which the patient has been infected. [9] Under ideal program conditions, MDR-TB cure rates can ...
Treatment of latent TB infection typically involves using a single drug for a prolonged period of time—the most common approach is Isoniazid for 9 months. Treatment of active TB disease is typically a combination of antibiotics, which results in patients being non-infectious to others usually within a few weeks.
If these drugs are misused or mismanaged, multidrug-resistant TB (MDR-TB) can develop. MDR-TB takes longer to treat with second-line drugs (i.e., amikacin, kanamycin, or capreomycin), which are more expensive and have more side-effects. XDR-TB can develop when these second-line drugs are also misused or mismanaged and become ineffective.